Category: Corona Virus Vaccine

Hospitals in the Japanese prefecture of Osaka no longer have empty beds available for severe Covid-19 patients, according to government data.

Osaka's bed occupancy rate for severe coronavirus patients hit 103% on Wednesday, per data posted on the Osaka government's website. The bed occupancy rate for mild and moderate cases is 82.4%.

To cope with the rising number of cases, the government opened two waiting centers in April with ventilators for patients who called for ambulances but could not be admitted due to a lack of beds.

Authorities also asked neighboring prefectures to accept patients with severe symptoms to ease Osaka's burden, but so far, only Shiga prefecture has participated. They've only accepted one patient.

Since the latest wave of infections began on March 4, 17 Covid-19 patients have died at home or in hotels, according to the government.

Osaka authorities said 13,992 Covid patients remain at home while 2,958 are waiting to be hospitalized or put in hotel rooms.

Hotel spaces are offered to those who cannot be hospitalized or those who need to be away from home and their families while infectious. Local health centers provide patients at home and hotels with oxygen meters and have them monitor and report to the health center.

The Osaka government also asked for nurses from around the country to come help with the rising number of cases. So far, more than 40 nurses have answered. The government website continues to have a nurses wanted recruitment notice for those who can work in the red zone of hospitals and capable of dealing with respirators."

The government said they will be paid a higher wage than normal.

View original post here:

The latest on Covid-19 and India's worsening crisis: Live updates - CNN International

Across the U.S., vaccines are going into arms. Mask and physical distancing guidelines are easing. And people are going back to work and school.

But is it time yet? Tentatively, yes, according to new research that projects possible scenarios for the future of the COVID-19 pandemic.

A team of infectious disease modelers at Northeastern has been answering that question for the U.S. government. Since January, the group has been developinga set of predictive models to project the future of the outbreak in various scenarios for the U.S. Centers for Disease Control and Prevention as part of a network of expert disease modeling teams across the country. Their results underpin policymakers decisions on when, how, and how quickly to lift pandemic restrictions.

The numbers are, in a sense, encouraging, says group leader Alessandro Vespignani, Sternberg Family distinguished university professor of physics, computer science, and health sciences, and also director of the Network Science Institute at Northeastern. The numbers from the ground align pretty well with what we are seeing.

On Wednesday, the CDC shared the latest projections from the team in the Morbidity and Mortality Weekly Report and during the White House press briefing by White House COVID-19 Response Team and Public Health Officials.

Something Im often asked is when will this pandemic be over and when will we go back to normal, director of the CDC, Rochelle Walensky, said during the briefing. The models forecasted some really good news, and an important reminder. The reality is it all depends on the actions we take now.

This latest round of results projected the number of deaths, hospitalizations, and cases of COVID-19 overall for the six-month period from April to September 2021 in the U.S. across four different scenarios of vaccination rates and levels of non-pharmaceutical interventions (masks, physical distancing, etc.). At the beginning of this month, there were just under 350,000 new COVID-19 cases in a week. Under a low vaccination, low non-pharmaceutical intervention scenario, Northeastern researchers project that weekly national cases could drop to about 125,000 by July. But if vaccination rates are high, weekly cases could drop below 50,000 by July and might even drop below 10,000 by August, under the most optimistic scenarios.

So far, the projections have held the test of time, Vespignani says.

At the end of March, the results were telling us there could be bumps on the road, he says. Depending on how quickly a state reopens, and the spread of new variants of the coronavirus, such as the B.1.1.7. variant that was first detected in the U.K., the models were suggesting possible surges in cases. And indeed, in April, this is what happened. We started to observe this surge of cases and a bit of surge of hospitalizations.

But, notably, Vespignani says, death rates and more severe cases are going down. There was a decoupling between the number of cases and the deaths and hospitalizations, he says. And this reflects vaccination rates against SARS-CoV-2, the coronavirus that causes COVID-19 in more vulnerable populations. The vaccination was protecting the people that were the most at risk, he says. Those vaccines are working like a charm.

The alignment of the scenarios and real data is a hopeful sign, as the models suggest that something resembling normal life could resume by July in the U.S. if people proceed cautiously, Vespignani says.

Or, Walensky said, we could return to normal sooner, if enough people get vaccinated quickly. The results remind us that we have the path out of this, she said, and models once projecting really grim news now offer reasons to be quite hopeful for what the summer may bring.

Five weeks into this latest set of scenario projections, Vespignani says, the future is brightening. We see a sustained decrease of cases in most of the places, and states that had a bit of surge were quickly reverting to smaller numbers in the last week or so.

Thats not to say we should lift all restrictions just yet, Vespignani says. You dont want to rush. We cannot exclude that if you do reopen too much, you can have surges. We need to constantly monitor that trend, the possible emergence of new variants of concern, and vaccination rates, he says. But, at this point, I think, it could be just a matter of weeks.

For media inquiries, please contact Jessica Hair at j.hair@northeastern.edu or 617-373-5718.

Read the original post:

When will the COVID-19 pandemic end? It depends on what people do as coronavirus restrictions ease. - News@Northeastern

DUBLIN--(BUSINESS WIRE)--The "PCR and Realtime PCR testing Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

The global PCR and realtime PCR testing market is expected to decline from $22.53 billion in 2020 to $9.98 billion in 2021 at a compound annual growth rate (CAGR) of -55.7%.

The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $13.82 billion in 2025 at a CAGR of 8.5%.

The RT-PCR test is necessary for qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens that is collected from individuals suspected of COVID-19.

The need for early detection of chronic diseases is expected to drive the market. With the onset of chronic diseases, there has been a priority to detect the cause of the disease to decrease its onset on people, for the drug discovery and to start the appropriate treatment at the appropriate time, which enables faster cure and also save maximum lives and decreases its after-effects. The RT-PCR test is the standard test for the recent COVID-19 (corona virus) pandemic. It is used for its high sensitivity, which enables it to detect early infection. Therefore, the need for early detection is propelling the PCR and real time PCR testing market.

Development of alternative technologies is expected to hinder the growth of PCR and real time PCR testing market. New technologies such as CRISPR, which is a rapid test is expected to be launched soon. In February 2020, Sherlock Biosciences Inc. and Mammoth Biosciences are trying to launch improved diagnostics with CRISPR-based technologies that would increase and accelerate the detection of the corona virus to treat the patients better and also to control the further spread of the virus. Development of alternative tests is expected to hinder the PCR and Real Time PCR Testing market.

Early detection plays a key role in treating COVID-19 patients. The real time RT-PCR technique is a highly sensitive and specific testing method that can deliver a reliable diagnosis in as fast as three hours, unlike the other laboratory tests that take an average of 6 to 8 hours. Real time RT-PCR is significantly faster and has a lower potential for contamination or errors as the entire process is within a closed tube. Therefore, currently it is considered to be the most accurate method available for detection of the coronavirus. This has created huge demand for PCR testing kits.

The companies in the PCR and RT PCR Testing market are coming up with new test kits and systems for the diagnosis of diseases. In January 2020, Roche got CE Mark approved for adenovirus test for the transplant patients. It is designed to be used along with other infectious diseases tests which can be used in their 6800 and 8800 cobas systems. Most companies are coming with the Real time RT-PCR test for corona virus, contributing to the growth of the PCR and Real time PCR Testing market.

Key Topics Covered:

1. Executive Summary

2. Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market Characteristics

3. Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market Trends And Strategies

4. Impact Of COVID-19 On Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing

5. Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market Size And Growth

5.1. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Forecast Market, 2020-2025F, 2030F, $ Billion

6. Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market Segmentation

6.1. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.2. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.3. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.4. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Segmentation By End-Use, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market Regional And Country Analysis

7.1. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Polymerase Chain Reaction (PCR) And Real-time Polymerase Chain Reaction (PCR) Testing Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/d42gbz

Read more here:

Global PCR and Realtime PCR Testing Market Report 2021: COVID-19 Impacts, Implications and Growth Forecast to 2025 & 2030 - ResearchAndMarkets.com...

A rising number of people whove been vaccinated are getting infected with the coronavirus. But is that surprising, and should it be cause for concern?

The short answer, according to local researchers: No.

Public health officials are tracking so-called COVID-19 breakthrough cases: fully vaccinated people whove become infected. It was already clear from the clinical trials that the current vaccines werent perfect. No vaccine is. But the rate of infection among the immunized has been extremely low, with COVID-19 hospitalization and death even less likely.

Researchers havent seen any alarming trends in these cases just further evidence that the current vaccines are highly effective.

The fact that there are breakthroughs is not a red flag, said Dennis Burton, an immunologist at Scripps Research. Breakthrough infections are to be expected, and the very small number indicates how very well the vaccines are providing protection.

To count as a breakthrough case, a person must have been infected at least two weeks after their second dose of the Moderna or Pfizer vaccines or the single-shot Johnson & Johnson vaccine. Thats about how long it takes for a vaccine to spark an antiviral response.

According to the latest report from the Centers for Disease Control and Prevention, 9,245 of the 95 million Americans who were fully immunized as of April 26 have tested positive for the coronavirus.

Thats an infection rate of less than one out of every 10,000 people. About 2,500 of those cases had no symptoms, 594 were hospitalized and 112 died of COVID-19.

The local situation mirrors the national picture, though on a smaller scale. San Diego County has had 234 breakthrough cases, 55 percent of whom havent had any COVID-19 symptoms. None of these people have been hospitalized or died, according to Dr. Seema Shah, medical director of the countys epidemiology division.

More than 1 million San Diegans have been fully vaccinated, putting the local breakthrough rate at about 0.02 percent.

The actual numbers are likely higher, as it takes time for public health departments to detect and report these cases. And asymptomatic infections often go unnoticed unless that person happens to get tested. Still, by any measure, the rate of breakthrough infections is low.

If youve ever gotten an influenza vaccine and still wound up with the flu, you know firsthand that no vaccine is 100 percent effective. In those moments, its tempting to think the shot didnt work. After all, if it had, you wouldnt have gotten sick, right?

Wrong, according to Shane Crotty, a researcher at La Jolla Immunology.

Ive had people tell me, Oh, I got infected, so the vaccine didnt work. And, no, thats really an example of the opposite, he said. You would have been so much more sick.

Crotty cites vaccine trial data and a growing body of research showing that coronavirus vaccines reduce your risk and severity of infection. In other words, people who might otherwise have died are surviving hospitalization, people who would have gone to the hospital are recovering at home, and those who would have had mild symptoms arent having any.

Clinical trials showed that the Pfizer and Moderna vaccines are about 95 percent effective in preventing illness, and that the Johnson & Johnson vaccine is roughly 66 percent effective. If those studies, which enrolled tens of thousands of people, saw breakthrough cases, then it was a matter of time until these cases appeared in the wider population now that millions of people are being immunized each day in the U.S.

As scientists detect more of these cases, theyll look for evidence theyre linked to certain demographics, vaccines or viral variants. There has been one notable example of that in South Africa, where AstraZenecas vaccine is only 10 percent effective against the fast-growing coronavirus strain first spotted in that country, according to a study published in the New England Journal of Medicine.

So far, there are no such signs in San Diego or elsewhere in the U.S. While most local cases have been detected among health care workers, thats probably because routine testing is more common in health care than in other sectors. And its too early to say whether certain strains are consistently evading current vaccines based on local data, according to Shah, as only a handful of samples have been sequenced.

There are a few reasons a fully vaccinated person could still get infected. One is that they were exposed to so much virus that their immune system couldnt quickly clear all of it.

Theres a huge range in the amount of virus that might be breathed on from one person to the other, Crotty said. Thats definitely a significant part of it.

Another factor is the dizzying degree of variation in peoples immune systems based on genetics, underlying health conditions and age, among other contributors.

No two immune responses will be the same, said Sujan Shresta of La Jolla Immunology, who studies immune responses to dengue and Zika virus. Some people will mount a really vigorous immune response that completely gets rid of the virus . (others) will get rid of maybe half of the virus, and then another arm of the immune system needs to come in.

Those who quickly clear the virus may have higher levels of antibodies, Y-shaped immune proteins that grip the surface of a virus and, if they latch on tightly enough at the right spot, can prevent infection.

But people who dont make the right kind of antibody response or who do, but in low amounts can still control an infection in other ways. That often involves T cells, which kill infected cells before they spew out more virus.

Crottys lab has found that, while a two-pronged attack of T cells and antibodies works best against the coronavirus, a strong T cell response alone can still limit the severity of infection.

That study was conducted before the start of the vaccine rollout. The La Jolla Immunology team is now looking for people with breakthrough infections who are willing to provide blood samples, which researchers will use to better understand antibody and T cells responses in these cases and why they werent enough to prevent infection.

As researchers learn more about why and when breakthrough cases occur, Burton of Scripps Research says theres a simple step you can take to prevent these infections: get vaccinated. The shot will reduce your chances of getting ill, he says, and it will also make you less likely to infect people who may not have strong vaccine responses such as those living with autoimmune disease or cancer.

The presence of breakthrough infections indicates the importance of everyone getting vaccinated so that we protect the weakest in society.

Continue reading here:

So coronavirus vaccines arent perfect. Theyre still very, very effective - The San Diego Union-Tribune

NAIROBI, Kenya (AP) Africa is watching with total disbelief as India struggles with a devastating resurgence in COVID-19 cases, the continents top public health official said Thursday, as African officials worry about delays in vaccine deliveries caused by Indias crisis.

The African continent, with roughly the same population as India and fragile health systems, must be very, very prepared since a similar scenario could happen here, John Nkengasong, director of the Africa Centers for Disease Control and Prevention, told reporters.

What is happening in India cannot be ignored by our continent, he said, and urged African countries to avoid mass gatherings including political rallies. We do not have enough health care workers, we do not have enough oxygen, he warned.

Africas vaccine supply heavily relies on India, whose Serum Institute is the source of the AstraZeneca vaccines distributed by the global COVAX project to get doses to low- and middle-income countries. Indias export ban on vaccines has severely impacted the predictability of the rollout of vaccination programs and will continue to do so for the coming weeks and perhaps months, Nkengasong said.

We are living in a world that is extremely uncertain now, he added.

Just 17 million vaccine doses have been administered across the African continent for a population of some 1.3 billion, according to the Africa CDC.

The situation in India is very sad to observe, the World Health Organizations Africa chief told reporters in a separate briefing. We are very concerned about the delays that are coming in the availability of vaccines, Matshidiso Moeti added.

Her WHO colleague, Phionah Atuhebwe, called the delay quite devastating for everybody and said most African nations that received their first vaccine doses via COVAX will reach a gap in supply while waiting for second doses as early as May or June.

We call upon countries that have extra doses to do their part, Atuhebwe said, adding that the WHO is reviewing the Chinese-made Sinopharm and Sinovac vaccines this week.

One unexpected COVID-19 vaccine donor is Congo, which Nkengasong said wants to give back some 1.3 million doses so they can be distributed to other African nations since it hasnt been able to do it at home.

There is a lot of vaccine hesitancy in the vast country, Nkengasong said. He didnt immediately know how many people have received the doses there.

There is a five-week timeline to get the doses administered elsewhere, he said, and Congo is working with COVAX to hand them over. He expressed hope that the doses can reach other people quickly during what he called an extremely critical time.

Nkengasong didnt know of other African countries saying theyre unable to use their doses but he urged them not to wait until the last moment to hand them back. Other countries in Europe, North America and Asia can have their luxury of vaccine options, he said, but we do not have choices.

Moeti with the WHO commended Congo for its decision, calling it extremely wise of the government to make this estimation in a country with gaps in its health care system.

She also warned that African countries must step up key public health measures to help avoid Indias scenario occurring here. The rate of testing for the coronavirus has dropped in quite a few countries, she said, and mentioned seeing data from one African nation in which the proportion of people not wearing face masks has risen to almost 80%.

Only 43 million tests for the virus have been conducted across the African continent since the pandemic began, the Africa CDC chief said, with a 26% drop in new tests conducted in the past week.

Nkengasong warned against travel bans, however, after Kenya this week announced it will suspend all passenger flights to and from India for two weeks starting midnight Saturday, while cargo flights continue.

Its really unfortunate we are reacting in a very ad hoc manner in respect to flight movements, he said, emphasizing the strength of authentic negative PCR tests. Its not people who are a threat, its the virus.

See the original post here:

Alarm grows in Africa as it watches India's COVID-19 crisis - The Associated Press

This virus is going to hang around for another couple of years before the world suppresses it, if were lucky, Fauci told me. I cant guarantee that well get a universal vaccine in place for this virus, but certainly we need it for the next one.

A universal SARS-CoV-2 vaccine may prove necessary to end this pandemic. Its also possible that the current generation of SARS-CoV-2 vaccines will hold up pretty well, and well require only a basic booster here and there. But even when this particular coronavirus has been suppressed, well still need to find a way to protect ourselves against others that lie in wait.

Thousands of related pathogens are estimated to be circulating among various nonhuman species, and some could make the jump to us at any time. In just the past 18 years, three coronaviruses have caused devastating human diseases (SARS, MERS, and COVID-19). Its not a question of if but when another pandemic coronavirus emerges, Martinez says.

Bjorkman shares this certainty. This isnt going to be the last one, she says. Were going to have SARS-CoV-3 and SARS-CoV-4. Everyone said this before the current pandemic. Most of the world ignored them. To do so again would really be burying your head in the sand.

The technology already exists to create a vaccine that protects humans from many coronaviruses at once. Vaccinating against all of them is a more elaborate challenge than taking on one or a few, but hypothetically possible. The broadest vaccine, though, isnt likely to come from discovering a single, conserved region of the spike protein that all coronaviruses share, and that also reliably stimulates our immune system. This would be something like finding one spot that will blow up the entire Death Stara little too easy. But we could find an array of frequently conserved regions that turn up in many coronaviruses.

The act of loading multiple targets into one vaccine is not difficult, according to Bjorkman. The postdocs in her lab can quickly create the proteins at the head of the spike and attach them to nanoparticles. Theyre really easy to make, she says modestly. The central challenge is in knowing which targets to include and making sure that they stimulate the immune system effectively.

The real issue is better understanding the universe of coronaviruses, says Wayne Koff, a biochemist and the head of the Human Vaccines Project. Its theoretically possible to learn the major changes in the viral genome that make them most likely to spread widely and devastatingly in humans, so that our bodies can develop at least partial recognition of whichever dangerous new coronaviruses may come along: What were especially concerned about are the coronaviruses that we dont even know about yet.

Koff believes we can figure out which common features or mutations could allow for such a vaccine, as we understand the coronavirus family tree at a more and more granular level. If animal ecologists can gather enough data from the field, you create an algorithm to find the ones that have the greatest potential to jump species, and then the ones that would kill people, he says. In his vision, supercomputing and advances in machine learning and modeling would accelerate the predictive process.

Read the original post:

Finding the Universal Coronavirus Vaccine - The Atlantic

The Columbia/Boone County Department of Public Health and Human Services is reporting nine new COVID-19 cases.

There are currently 90 active cases in the county.

The county now has a reported total number of COVID-19 cases of 18,286.

The county has reported the total number of cases removed from isolation is 18,110.

The Columbia/Boone County Department of Public Health and Human Services dashboard has reported the latest five-day average as 10.

The county continues to trend down as there have been 91 straight days of single or double-digit case increases.

The health department is reporting the total number of hospitalizations in Boone County is 12.

The health department is reporting one Boone County resident are in the hospital due to the coronavirus.

The dashboard is reporting two COVID-19 patients in the ICU and one patient on a ventilator.

The hospital status remains in 'Green' status. 'Green' status is when hospitals are operating within licensed bed capacity; accepting patient transfers from referring hospitals within standard care operating procedures.

The State of Missouri coronavirus vaccine dashboard is reporting that 78,761 residents have received their first dose in Boone County and 59,502 Boone County residents have completed their vaccine doses.

Boone County has the largest percentage of people in Mid-Missouri that have received at least one dose of the vaccine with 43.6%. The second closest in the state is St. Louis County with 39.8%.

Boone County has a reported 33% of residents that have completed their coronavirus vaccine doses, tied for first in the state. Atchison County also has 33% of residents having completed the the doses for vaccination.

Cole County has the second-highest first vaccination rate in Mid-Missouri with 34.3%. Montgomery County is third with 31.8%.

The Missouri Department of Health and Senior Services reported more than 500 confirmed new coronavirus cases Thursday and nearly 300 new probable cases.

The state logged 521 positive PCR tests, which are considered confirmed cases, on Thursday. Missouri reported another 274 positives on antigen tests, which are considered probable cases but not confirmed.

The number of new confirmed cases is more than 200 cases higher than the daily average of new cases reported on the department's coronavirus dashboard. The dashboard average is based on the date of the test, not the day the result was reported.

The state has now reported 501,106 confirmed coronavirus cases since the pandemic started last March. Missouri reported four new deaths for a total of 8,738 since the pandemic started.

The department reports Boone County is No. 17 for cases per 100,000 people over the last seven days and Callaway County is No. 19.

The state ranks No. 26 in the number of new cases per 100,000 people over the last seven days, according to the state dashboard. The positivity rate -- the percentage of coronavirus tests that come back positive -- increased slightly to 4.7%.

More than 37% of state residents have at least gotten one shot of the coronavirus vaccine, though the number of shots administered daily has dropped sharply this month. Boone County remains at the top for highest percentage of the population starting vaccination at 43.6%.

Read more:

THURSDAY UPDATES: Boone County first in state with beginning and completing coronavirus vaccine with percent of population - ABC17NEWS - ABC17News.com

About one in ten Americans are not showing up for their second dose.

SAN ANTONIO Coronavirus vaccination numbers have come down considerably across the country. We know many have decided not to get the vaccine at all, but there is a new problem emerging where those who got the first dose of a vaccine are skipping the second one.

Two studies conducted by Oxford University found that protection from getting only one dose of a two dose vaccine only lasts about ten weeks. And with close to one out of every ten people not going back for their second dose, and many not getting vaccinated at all, that doesn't bode well for this pandemic.

"We need as many people to get vaccinated as possible. Right, to prevent these endemic kind of waves where we see more people know the surge and it comes down a little bit then another surge," said Dr. Jason Bowling, an Associate Professor of Infectious Diseases at UT Health San Antonio.

And getting that second dose after the first is imperative.

"There's data now showing that it doesn't last as long," Dr. Bowling said. "You want the protection to last as long as possible. The other factor is that with these variants that are starting to circulate, and we're learning more about, some of them can decrease how effective the vaccine works."

A Kaiser Family Foundation report found that as of last week close to 42 percent of Americans have had at least one dose of a vaccine, and that only 35 percent of adults are fully vaccinated, or about 27 percent of the population. And with 20 percent of the U.S. considered 'vaccine hesitant' warned the U.S. is nearing a tipping point.

"Do yourself a favor, get the full protection right. To protect yourself and your family," Dr. Bowling said.

Invisibly used Realtime Research to poll 1258 people. They found parents ages 18 to 24 are the most likely to get their kids vaccinated, and found a whopping 47 percent said they would not get their kids a COVID vaccine.

"One of the issues is that a lot of the vaccines to date so far has been in these large mass vaccine hubs. But if we can transition this to physician offices, that might help so that people can talk to their provider about it," Dr. Bowling added.

He also said that for those who are fully vaccinated the jury is still out on when it will be time for a booster. But clinical trials have shown the vaccine is still about 90 percent effective after six months.

Originally posted here:

Coronavirus vaccination numbers are on the decline - KENS5.com

More:

Emerging Markets Report: The Rich Get Richer

Excerpt from:

MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions;...